Get the app
US › Healthcare

Zentalis Pharmaceuticals Llc (ZNTL)

US · Healthcare · Biotechnology

$2.13-4.91%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-77.6M
EPS
$-0.59
EPS estimate
$-0.45

EPS came in at -0.59 against a street estimate of -0.45 — a miss of 31.1%.

Key statistics

Market cap
$259.0M
Forward P/E
0.0
P/B
1.89
Book value
$2.00
EPS (TTM)
$-1.96
52-week high
$6.95
52-week low
$1.21
50-day MA
$3.56
200-day MA
$3.45
Beta
1.94

Analyst view

Analysts rate Zentalis Pharmaceuticals Llc a buy (7 buy, 4 hold, 0 sell out of 11) with an average price target of $7.33.

Shareholding

Insiders
21.85%
Institutions
50.86%

Largest institutional holders

FundStake
5AM Venture Management, LLC4.02%
BlackRock Inc3.83%
Squadron Capital Management LLC3.77%
Two Sigma Investments LLC3.08%
Vanguard Capital Management, LLC2.89%
Acadian Asset Management LLC2.73%
Citadel Advisors Llc2.34%
Renaissance Technologies Corp1.64%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zentalis Pharmaceuticals Llc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.